A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients

Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke as measured by the planned analyses. Post hoc analyses suggest that a modest treatment effect may have been seen if more traditional analyses had been used.